Wednesday, May 03, 2006

Improving hypertension control...An emerging approach to metastasis

Today' s edition of DailyUpdates features over 40 breaking journal articles and drug development news items across multiple therapeutic area. We have selected two, one describing advances that should lead to better control of hypertension, and another announcing the advance of a promising oncology candidate that appears to block metastasis. To view today's edition of DailyUpdates please click here, or alternatively read on for more on our selected items

Featured Journal Article (from DailyUpdates - Cardiovascular Disease) - Predictors of adverse outcome among patients with hypertension and coronary artery disease
: LeadDiscovery's recent feature Hypertension markets and therapeutics estimates that there are currently 192m people with hypertension in the seven major markets, and this number is set to rise to 212m by 2015. Yet, a significant fraction of this sizeable patient pool remains undiagnosed or aborts treatment. Optimizing the use of antihypertensives thus remains a clinical objective. This is likely to involve the treatment of a higher proportion of patients with hypertension and also the optimization of treatment choice in individuals. The latter will hopefully improve the befit:risk/adverse effect relationship and in turn improve adherence and safety. Today's featured journal article (J Am Coll Cardiol. 2006 Feb 7;47(3):547-51) reports on predictors for adverse outcomes in hypertensive patients with coronary artery disease. This study is of considerable importance, not least due to the large numbers of patients with both conditions.

Breaking News (from DailyUpdates-Oncology): Candidate treatment of metastasis advances through the clinic: Metastasis is a major cause of morbidity and mortality in human malignancies. Sites of metastasis vary according to the primary tumor however vital organs including the brain, liver and lungs as well as bone are commonly affected. Preventing metastasis currently depends on the reduction of the number of cancerous cells to a level that can be regulated by the body's defense system. The development of therapeutics that actively target the metastatic process is therefore crucial. Chemokine Therapeutics are amongst the leaders in this field and today they announce (see release) that it has started patient dosing in a phase Ib/II clinical trial using CTCE-9908. The trial will involve up to 30 patients with late stage cancers to evaluate safety and preliminary efficacy. CTCE-9908 blocks the binding of SDF-1 to CXCR4 and in preclinical studies CTCE-9908 has been shown to reduce cancer metastases by 50-70% and to have demonstrated early evidence of potential anti-angiogenic properties. The development of CTCE-9908 raises a few interesting question such as do metastases metastasize and would candidates targeted against metastasis be expected to demonstrate efficacy in patients who already have metastatic disease?


Post a Comment

<< Home